Skip to main content

Accelrys, Agilent Partner to Resell Each Other's Software to Pharma

NEW YORK (GenomeWeb News) - Accelrys and Agilent Technologies said yesterday that they have struck an agreement to resell each other's software to pharmaceutical companies through an integration and licensing agreement.
Under the agreement, Accelrys will resell Agilent's OpenLAB enterprise content manager, Kalabie electronic lab notebook, and GeneSpring gene expression software. Agilent will resell Accelrys' Accord cheminformatics solutions and Pipeline Pilot scientific operating platform.
"Agilent's strength in laboratory Informatics, QA/QC, and manufacturing are a natural complement to Accelrys' expertise in research, early development, and scientific data management," said Accelrys CEO Mark Emkjer.
Agilent's vice president and general manager, Bruce von Herrmann, said the integrated license and joint resale deal will benefit pharmaceutical clients "that want to spend less time integrating existing informatics solutions and more time developing new, more effective medicines."
Financial terms of the agreement were not released.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.